@article{0e9b753323f44385b6f6b58b82bf71d4,
title = "The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures",
abstract = "In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia. However, more information regarding psychometric properties and correlations with standard neuropsychological tests and functional measures is warranted to establish their validity as treatment outcome measures. The N-back and AX-Continuous Performance Task (AX-CPT) are two promising cognitive neuroscience tests designed to measure specific components of working memory and contextual processing respectively. In the current study, we report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological measures and functional capacity measures. The results suggest that while the AX-CPT and N-back display favorable psychometric properties, they do not exhibit greater sensitivity or specificity with functional measures than standard neurocognitive tests.",
author = "Kraus, {Michael S.} and Gold, {James M.} and Barch, {Deanna M.} and Walker, {Trina M.} and Chun, {Charlotte A.} and Buchanan, {Robert W.} and Csernansky, {John G.} and Goff, {Donald C.} and Green, {Michael F.} and Jarskog, {L. Fredrik} and Javitt, {Daniel C.} and David Kimhy and Lieberman, {Jeffrey A.} and McEvoy, {Joseph P.} and Mesholam-Gately, {Raquelle I.} and Seidman, {Larry J.} and Ball, {M. Patricia} and Kern, {Robert S.} and McMahon, {Robert P.} and James Robinson and Marder, {Stephen R.} and Keefe, {Richard S.E.}",
note = "Funding Information: This study was funded by National Institute of Mental Health Contract HHSN278200441003C to the University of California, Los Angeles (SRM, Principal Investigator). Double-blind medications were provided by Merck and Company. Funding Information: Dr. McEvoy has received research grant funding from Alkermes, BoehringerIngelheim, Neurocrine, Takeda, and TEVA and has given disease state talks for Neurocrine. Funding Information: In the past 3 years, Dr. Jarskog has received research grant funding from Auspex/Teva, Boehringer-Ingelheim and Otsuka. Funding Information: Dr. Richard Keefe currently or in the past 3 years has received honoraria, served as a consultant, speaker, or advisory board member for Abbvie, Acadia, Aeglea, Akebia, Akili, Alkermes, Allergan, ArmaGen, Astellas, Avanir, AviNeuro/ChemRar, Axovant, Biogen, Boehringer-Ingelheim, Cerecor, CoMentis, Critical Path Institute, FORUM, Gammon Howard & Zeszotarski, Global Medical Education (GME), GW Pharmaceuticals, Intracellular Therapeutics, Janssen, Kempharm, Lundbeck, Lysogene, MedScape, Mentis Cura, Merck, Merrakris Therapetics, Minerva Neurosciences Inc., Mitsubishi, Montana State University, Monteris, Moscow Research Institute of Psychiatry, Neuralstem, Neuronix, Novartis, NY State Office of Mental Health, Orygen, Otsuka, Paradigm Testing, Percept Solutions, Pfizer, Pharm-Olam, Regenix Bio, Reviva, Roche, Sangamo, Sanofi, SOBI, Six Degrees Medical, Sunovion, Takeda, Targacept, Teague Rotenstreich Stanaland Fox & Holt, Thrombosis Research Institute, University of Moscow, University of Southern California, University of Texas Southwest Medical Center, WebMD, and Wilson Therapeutics. Dr. Keefe has currently or in the past 3 years received research funding from the National Institute of Mental Health and Boehringer-Ingelheim. Dr. Keefe receives royalties from versions of the BAC testing battery, the MATRICS Battery (BACS Symbol Coding), and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). He is also a shareholder in NeuroCog Trials, Inc. and Sengenix. Funding Information: This study was funded by National Institute of Mental Health Contract HHSN278200441003C to the University of California, Los Angeles (SRM, Principal Investigator). Double-blind medications were provided by Merck and Company. Funding Information: Dr. Lieberman neither accepts nor receives any personal financial remuneration for consulting, speaking or research activities from any pharmaceutical, biotechnology or medical device companies. He receives support administered through Columbia University and the Research Foundation for Mental Hygiene in the form of funding and medication supplies for investigator initiated research from Denovo, Taisho, Pfizer, Sunovion, and Genentech, and for company sponsored phase II, III and IV studies from Alkermes, Allergan and Boehringer Ingelheim, and is a consultant to or member of the advisory board of Intracellular Therapies, Lilly, Pierre Fabre, Pear Therapeutics and Psychogenics for which he receives no remuneration. He is a paid consultant for Clintara, a clinical research services organization, and holds a patent from Repligen that yields no royalties. Publisher Copyright: {\textcopyright} 2019",
year = "2020",
month = mar,
doi = "10.1016/j.scog.2019.100161",
language = "English (US)",
volume = "19",
journal = "Schizophrenia Research: Cognition",
issn = "2215-0013",
publisher = "Elsevier Inc.",
}
